Report
DSM-Firmenich FIRST LOOK: 4Q adj EBITDA +37%, FY25 guidance of at least 13% growth
4Q adj EBITDA jumped by 37% and was about 2% better than our and consensus forecasts. Dsm-firmenich guides for at least 13% adj. EBITDA growth in FY25, on the back of a combination of synergies, savings and continued benefit from temporary high vitamin prices. The company is still looking to exit the ANH business and, reflecting the strong balance sheet, has announced a € 1bn share buyback program. We still appreciate dsm-firmenich for its broad portfolio and market leading positions. The upcoming separation of the Animal Nutrition & Health business can be a catalyst to unlock value and we maintain our Accumulate rating for now.
Underlying
KONINKLIJKE DSM N.V.
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Wim Hoste
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.